1. Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients.
- Author
-
Kegasawa T, Tatsumi T, Yoshioka T, Suda T, Ikezawa K, Nakabori T, Yamada R, Kodama T, Shigekawa M, Hikita H, Sakamori R, and Takehara T
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor analysis, Biomarkers, Tumor blood, Cell Line, Tumor, Female, GPI-Linked Proteins analysis, GPI-Linked Proteins blood, Humans, Intercellular Signaling Peptides and Proteins blood, Killer Cells, Natural pathology, Male, Middle Aged, Pancreas pathology, Pancreatic Neoplasms blood, Pancreatic Neoplasms pathology, Prognosis, Survival Analysis, Intercellular Signaling Peptides and Proteins analysis, Pancreatic Neoplasms diagnosis
- Abstract
The immune system plays important roles in pancreatic cancer. MHC class I-chain-related proteins A and B (MICA/B) and UL16-binding proteins (ULBPs) are known natural killer group 2D (NKG2D) ligands. Soluble NKG2D ligands can inhibit the activation of Natural killer (NK) cells. In pancreatic cancer, soluble ULBPs are relatively unstudied in contrast to soluble MICA/B. We examined the significance of soluble ULBPs, especially ULBP2, in pancreatic cancer. Soluble ULBP2 but neither soluble ULBP1 nor soluble ULBP3, was etected in the supernatants of pancreatic cancer cells. Soluble ULBP2 derived from pancreatic cancer cells could reduce the cytotoxicity of NK cells. Multivariate analysis demonstrated that serum soluble ULBP2 was a significant independent factor associated with poor overall survival (OS) in all pancreatic cancer patients, specifically in stage IV patients. In conclusion, pancreatic cancer-derived soluble ULBP2 might affect the prognosis in pancreatic cancer., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF